Physician profile
Jerald W Bybee
NPI 1659360816
$7,946.43
in general payments reported to CMS, 2019-2025
39 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $1,032 · 2021: $1,239 · 2022: $1,235 · 2023: $994 · 2024: $1,230 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.32 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,177.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,119.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,053.31 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $764.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $480.43 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $403.12 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.27 | 2019-2025 | Jardiance, Trijardy Xr, Tradjenta |
| Janssen Pharmaceuticals, INC | $343.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $322.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.14 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $205.09 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $170.53 | 2019-2025 | Zoryve |
| Mylan Specialty L.P. | $146.12 | 2019-2024 | Yupelri |
| Esperion Therapeutics, INC. | $111.39 | 2020-2022 | |
| Radius Health, INC. | $103.15 | 2019-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Bybee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.